Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …

Diabetes mellitus is a potent upstream event in the molecular pathophysiology which gives
rise to various diabetes-related complications. There are several classes of anti-diabetic …

Ketogenesis takes place in hepatocyte mitochondria where acetyl-CoA derived from fatty
acid catabolism is converted to ketone bodies (KB), namely β-hydroxybutyrate (β-OHB) …

This review discusses two distinct, yet related, mechanisms of sodium-glucose cotransporter
2 (SGLT2) inhibition: Calorie restriction mimicry (CRM) and pro-ketogenic effect, which may …

Hyperuricemia has been linked to metabolic syndrome, cardiovascular disease, and chronic
kidney disease. Hyperuricemia and type 2 diabetes mellitus were inter-related, type 2 …

Diabetic ketoacidosis is an infrequent but life-threatening acute complication of diabetes,
affecting predominantly patients with type 1 diabetes, children, and pregnant women, where …

Abstract Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) are newly approved class of
oral anti-diabetic drugs, in the treatment of type 2 diabetes, which reduces blood glucose …

Diabetes prevalence shows a continuous increasing trend in South Asia. Although well-
established treatment modalities exist for type 2 diabetes mellitus (T2DM) management, they …

Introduction: The use of antidiabetic drugs is expected to substantially increase since
diabetes mellitus incidence rises. Currently used antidiabetic drugs have a positive safety …

Introduction: Sodium-glucose co-transporter 2 (SGLT2) inhibitors inhibit glucose re-
absorption in the proximal renal tubules. These drugs also affect many anthropometric and …